CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acura Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acura Pharmaceuticals, Inc.
616 N. North Court
Suite 120
Phone: (847) 705-7709p:847 705-7709 Palatine, IL  60067-8121  United States Ticker: ACURACUR

Business Summary
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201812/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director Robert B.Jones 59 7/7/2011 4/7/2008
Chief Financial Officer, Senior Vice President, Secretary Peter A.Clemens 65 8/1/2004 2/19/1998
Vice President, Corporate Controller and Treasurer Robert A.Seiser 54 4/1/2004 3/1/1998
6 additional Officers and Directors records available in full report.

Business Names
Business Name
`Acura Pharmaceuticals, Inc.
ACUR
Acura Pharmaceutical Technologies, Inc.
Acura Pharmaceuticals, Inc.

General Information
Number of Employees: 14 (As of 12/31/2017)
Outstanding Shares: 21,300,192 (As of 9/12/2019)
Shareholders: 301
Stock Exchange: OTC
Federal Tax Id: 110853640
Fax Number: (847) 705-5399
Email Address: investor@halseydrug.com


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, September 20, 2019